Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 5/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | WNT1 | P04628 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10235139 | 0.92 | FAAH (0.55) | FAAHSCN10APPARGCNR1NR3C1 | |
| SCHEMBL17970235 | 0.92 | FAAH (0.53) | FAAHSCN10APPARGCNR1NR3C1 | |
| SCHEMBL9958835 | 0.89 | FAAH (0.68) | FAAHPLA2G2AMAPTPTGDR2 | |
| SCHEMBL9952599 | 0.89 | FAAH (0.59) | FAAHSCN10APPARGCNR1PLA2G2A | |
| SCHEMBL9959066 | 0.89 | FAAH (0.72) | FAAHCNR1PLA2G2AP2RX3MAPT | |
| SCHEMBL9959314 | 0.88 | FAAH (0.59) | FAAHSCN10ACNR1NR3C1P2RX3 | |
| SCHEMBL9953347 | 0.85 | FAAH (0.77) | FAAHSCN10ACNR1MAPK3PLA2G2A | |
| SCHEMBL9959580 | 0.85 | FAAH (0.65) | FAAHPLA2G2AMAPT | |
| SCHEMBL9958535 | 0.84 | FAAH (0.54) | FAAHSCN10APPARGNR3C1PLA2G2A | |
| SCHEMBL9956264 | 0.84 | FAAH (0.55) | FAAHSCN10APPARGCNR1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657012-B2 | FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657012-B2 | FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657012-B2 | FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2655356-B1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS INC (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2655356-B1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20150175599-A1 | FAAH Inhibitors | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175599-A1 | FAAH Inhibitors | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2014004676-A1 | USE OF FAAH INHIBITORS AS NEUROPROTECTIVE AGENTS IN THE CNS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| EP-2655356-A1 | FAAH INHIBITORS | Ironwood Pharmaceuticals, Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012088469-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088469-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175599-A1 | FAAH Inhibitors | FAAH, FAAH2, ASAH1 | FAAH 1/4885SCN10A 1371/4885PPARG 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.